

<https://doi.org/10.48047/AFJBS.6.2.2024.4357-4363>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

Minimally Invasive Management of Achalasia: Insights into Laparoscopic Heller's Cardiomyotomy with Fundoplication

Peter Hany Wasef Daoud, Samir Ibrahim Mohammed, Abdelwahab Saleh Abdelwahab, Mohammed Farouk Amin

General Surgery Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Peter Hany Wasef Daoud

Email: peterhany2009@gmail.com

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 5 August 2024

Accepted: 15 August 2024

Published: 15 August 2024

[doi:10.48047/AFJBS.6.2.2024.4357-4363](https://doi.org/10.48047/AFJBS.6.2.2024.4357-4363)

Abstract: Achalasia of the cardia is a rare esophageal motility disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and loss of esophageal peristalsis, leading to dysphagia, regurgitation, and chest discomfort. Among various treatment modalities, laparoscopic Heller's cardiomyotomy combined with fundoplication has emerged as a gold-standard surgical intervention. This review examines the efficacy, safety, and outcomes of this procedure in the management of achalasia, focusing on operative techniques, perioperative considerations, and long-term results. The article explores the benefits of minimally invasive approaches in reducing postoperative complications, enhancing recovery, and improving quality of life. It also discusses the role of fundoplication in preventing gastroesophageal reflux disease (GERD), a common complication post-cardiomyotomy, and compares different fundoplication techniques. Furthermore, the review evaluates patient selection criteria, success rates, and potential challenges, including recurrent symptoms and management of advanced cases. By synthesizing evidence from recent studies, this review aims to guide clinicians in optimizing surgical outcomes for achalasia patients through tailored approaches and multidisciplinary care.

Keywords: Achalasia, Laparoscopic Heller's Cardiomyotomy

Introduction

Achalasia is a rare esophageal motility disorder characterized by the loss of peristalsis in the distal esophagus and failure of the lower esophageal sphincter (LES) to relax adequately. The condition results in progressive dysphagia, regurgitation, chest pain, and weight loss. Surgical management aims to alleviate these symptoms by reducing the LES pressure and improving esophageal emptying. Various surgical options are available, with each tailored to the patient's disease severity, anatomy, and preferences [1].

The first-line surgical treatment for achalasia is laparoscopic Heller myotomy (LHM), a minimally invasive procedure involving the division of the LES muscle fibers. LHM provides durable symptom relief, especially when combined with a partial fundoplication to prevent gastroesophageal reflux disease (GERD). The procedure has a high success rate, with studies showing significant symptom improvement in 85-90% of patients over a long-term follow-up [2].

Another emerging surgical option for achalasia is peroral endoscopic myotomy (POEM). This technique involves creating a submucosal tunnel in the esophagus to access and divide the LES. POEM offers similar symptom relief as LHM and may be advantageous in certain patient populations, such as those with a tortuous esophagus or failed previous interventions. However, POEM has a higher incidence of postoperative GERD, which requires effective management [3].

The choice between LHM and POEM often depends on factors such as the surgeon's expertise, patient anatomy, and individual preferences. Studies comparing the two techniques indicate equivalent outcomes regarding symptom control and complication rates. However, the long-term risk of GERD appears to be higher with POEM, emphasizing the importance of careful patient selection and follow-up [4].

For patients with advanced or end-stage achalasia (also known as sigmoid esophagus), esophagectomy may be considered. This procedure involves resection of the affected esophagus and reconstruction using a gastric or colonic conduit. While esophagectomy is a more invasive option, it may be the only feasible solution for patients with severe esophageal dilation or fibrosis that precludes other treatments [5].

Balloon dilation is a less invasive alternative to surgical myotomy, often reserved for patients who are not candidates for surgery. During this procedure, a pneumatic balloon is inflated at the LES to disrupt the muscle fibers. While effective in relieving symptoms temporarily, dilation may require repeated sessions and carries a risk of esophageal perforation [6].

Botulinum toxin (Botox) injection into the LES is another palliative treatment option, particularly for high-risk surgical patients. Botox works by temporarily paralyzing the LES muscles, reducing their tone and resistance. Although effective in the short term, its benefits diminish over time, necessitating repeated injections [7].

The choice of surgical management for achalasia also depends on the subtype of the disease, as identified by high-resolution manometry (HRM). Type I achalasia (classic) and Type II achalasia (with pan-esophageal pressurization) respond well to both LHM and POEM, while Type III achalasia (spastic) often requires tailored interventions, such as extended myotomy or pharmacological therapies, to address the heightened esophageal contractions [8].

Advances in imaging modalities, such as timed barium esophagogram and HRM, play a pivotal role in surgical planning and postoperative evaluation. These tools help assess esophageal emptying and guide the extent of myotomy, ensuring optimal outcomes for the patient. Postoperative follow-up typically involves symptom assessment, endoscopy, and pH monitoring to evaluate for GERD or recurrence of symptoms [9].

GERD is a common postoperative complication of achalasia surgery, particularly with POEM and LHM without fundoplication. Patients often require long-term proton pump inhibitor (PPI) therapy or additional anti-reflux procedures. The risk of GERD underscores the importance of combining surgical myotomy with fundoplication when feasible [10].

Patient counseling and shared decision-making are integral to the management of achalasia. Physicians should discuss the benefits, risks, and potential complications of each surgical option, ensuring that patients have realistic expectations about the outcomes. Individualized treatment plans based on the patient's health status, preferences, and disease characteristics often yield the best results [11].

Recent innovations in surgical techniques and equipment have further improved the safety and efficacy of achalasia management. Robotic-assisted surgery, for instance, enhances precision and reduces operative time, offering promising outcomes for complex cases. However, its high cost and limited availability remain challenges to widespread adoption [12].

Studies investigating long-term outcomes of surgical interventions for achalasia have highlighted the importance of regular follow-up. Recurrence of symptoms or progression to advanced disease stages can occur even after successful treatment, necessitating timely interventions such as repeat myotomy or esophagectomy [13].

The role of lifestyle modifications in managing postoperative symptoms should not be overlooked. Patients are advised to adopt dietary changes, such as consuming small, frequent meals and avoiding foods that exacerbate reflux. Elevating the head of the bed and maintaining a healthy weight also contribute to better outcomes [14].

Achalasia is a chronic condition with no definitive cure, making symptom control and quality of life improvement the primary goals of treatment. Surgical interventions address the mechanical obstruction caused by the non-relaxing LES, but they do not restore normal esophageal motility. This limitation highlights the need for ongoing research into novel therapies [15].

Combination therapies, such as myotomy with adjunctive pharmacological agents, are being explored to enhance treatment efficacy. Agents targeting specific pathways involved in esophageal motility and LES relaxation may offer additional benefits, particularly for patients with refractory symptoms [16].

The economic impact of achalasia management is another consideration. Surgical procedures like LHM and POEM involve significant upfront costs, but their long-term benefits in reducing symptom burden and improving quality of life often justify the expense. Cost-effectiveness studies can guide resource allocation and decision-making in healthcare systems [17].

Future research in achalasia management aims to refine existing surgical techniques and develop minimally invasive alternatives. Gene therapy and regenerative medicine hold potential for restoring normal esophageal function by targeting the underlying neuronal loss in the myenteric plexus [18].

Interdisciplinary care involving gastroenterologists, surgeons, dietitians, and psychologists is crucial for achieving optimal outcomes in achalasia management. Addressing both the physical and psychological aspects of the disease ensures comprehensive care for patients [19]. surgical management of achalasia encompasses a spectrum of options tailored to individual patient needs. While procedures like LHM and POEM have revolutionized treatment, challenges such as GERD and recurrence necessitate continuous advancements in surgical techniques and postoperative care. Collaboration between patients and healthcare providers remains the cornerstone of successful outcomes in this complex disorder [20].

Achalasia of the cardia is a rare esophageal motility disorder characterized by the inability of the lower esophageal sphincter (LES) to relax properly and the absence of effective peristalsis in the esophagus. This condition often leads to dysphagia, regurgitation, chest pain, and weight loss, significantly impairing the quality of life of affected individuals [21]. Laparoscopic Heller's cardiomyotomy combined with fundoplication has emerged as a highly effective surgical treatment for managing achalasia. This minimally invasive procedure alleviates symptoms by releasing the LES, thereby restoring the ability of the esophagus to transport food into the stomach while minimizing postoperative gastroesophageal reflux [22].

The pathophysiology of achalasia involves the degeneration of myenteric plexus neurons, which control the relaxation of the LES. This neuronal degeneration is often idiopathic but may have autoimmune or infectious etiologies. Diagnostic evaluation typically includes esophageal manometry, barium swallow, and endoscopy, with high-resolution manometry considered the gold standard [23]. Laparoscopic Heller's cardiomyotomy targets the hypertonic LES, addressing the mechanical obstruction caused by the dysfunctional sphincter [24]. Further understanding of the underlying pathophysiological mechanisms has led to improved diagnostic techniques, with advanced imaging modalities such as endoscopic ultrasound providing complementary insights into esophageal wall changes [41].

The laparoscopic approach to Heller's cardiomyotomy offers numerous advantages over traditional open surgery. These include reduced postoperative pain, shorter hospital stays, quicker recovery, and improved cosmetic outcomes. The addition of fundoplication, typically a Dor or Toupet procedure, mitigates the risk of gastroesophageal reflux, a common complication following myotomy [25]. Emerging data suggest that variations in surgical technique, such as extended myotomy into the gastric cardia, may further enhance outcomes, particularly in refractory cases [42].

Preoperative evaluation is critical in determining the suitability of patients for this procedure. Endoscopic and radiologic assessments ensure the exclusion of pseudoachalasia and other secondary causes of dysphagia. Moreover, nutritional optimization and management of esophageal stasis prior to surgery enhance postoperative outcomes [26]. Comprehensive preoperative counseling, including discussions about the potential risks and benefits, is equally important in optimizing patient expectations and adherence to postoperative care protocols [43].

During the procedure, the surgeon makes small incisions to access the esophagus and stomach. Pneumoperitoneum is established, and the esophagus is mobilized to expose the LES. The myotomy involves cutting the circular muscle fibers of the LES without compromising the mucosa. This delicate dissection requires advanced laparoscopic skills to avoid complications, such as mucosal perforation [27]. In addition, intraoperative endoscopy can be employed to confirm the adequacy of the myotomy and to detect mucosal injuries in real-time [44].

Fundoplication, performed immediately after the myotomy, prevents reflux by creating a partial or complete wrap of the gastric fundus around the lower esophagus. Dor fundoplication, a 180-degree anterior wrap, is preferred for its simplicity and lower risk of postoperative dysphagia. Toupet fundoplication, a 270-degree posterior wrap, is another effective option, particularly in patients with significant esophageal motility disorders [28]. Alternative techniques, such as Nissen fundoplication, are less commonly utilized due to the increased risk of dysphagia but may be appropriate in select cases [45].

Intraoperative complications are rare but may include mucosal perforation, bleeding, and injury to adjacent structures. Prompt recognition and management of these complications are essential. In the case of mucosal perforation, intraoperative repair is usually successful, and postoperative outcomes remain favorable [29]. Advances in surgical technology, such as energy devices and robotic assistance, have contributed to a further reduction in complication rates [46].

Postoperative care focuses on managing pain, preventing infection, and monitoring for complications such as persistent dysphagia or reflux. Patients are typically started on a liquid diet, progressing to a soft diet over the following weeks. Long-term follow-up with periodic endoscopy and manometry ensures sustained symptom relief and the early detection of complications [30]. Enhanced recovery after surgery (ERAS) protocols have been shown to accelerate recovery and improve patient satisfaction [47].

The outcomes of laparoscopic Heller's cardiomyotomy with fundoplication are generally excellent. Studies report symptom relief in over 90% of patients, with durable results extending over decades. Factors influencing success include patient age, the severity of esophageal dilation, and adherence to postoperative dietary recommendations [31]. Recent multicenter trials have confirmed the procedure's long-term efficacy, emphasizing the importance of personalized surgical approaches based on disease severity and patient characteristics [48].

Comparative studies highlight the superiority of laparoscopic Heller's cardiomyotomy over other treatment modalities, such as pneumatic dilation and peroral endoscopic myotomy (POEM). While POEM offers similar efficacy in symptom relief, it lacks an anti-reflux mechanism, making fundoplication a critical component in laparoscopic approaches [32]. Further comparative analyses have also identified cost-effectiveness as a significant advantage of laparoscopic techniques over endoscopic interventions [49].

Achalasia subtypes, as classified by the Chicago classification, influence treatment outcomes. Type I (classic achalasia) and Type II (with esophageal compression) typically respond better to myotomy, while Type III (spastic achalasia) may require additional interventions, such as extended myotomy or botulinum toxin injections [33]. The incorporation of novel diagnostic criteria into the Chicago classification continues to refine therapeutic decision-making and improve prognostic accuracy [50].

Patients with advanced disease, characterized by significant esophageal dilation and sigmoid-shaped esophagus, pose unique challenges. While myotomy can still provide symptom relief, these patients often require esophagectomy or other adjunctive procedures for optimal management [34]. Surgical innovations, such as colonic interposition and gastric pull-up, are alternative options for managing severe cases with end-stage esophageal dysfunction [51].

The role of robotic-assisted surgery in Heller's cardiomyotomy is evolving. Robotic systems offer enhanced dexterity and visualization, potentially improving outcomes in complex cases. However, the cost-effectiveness of robotic approaches compared to traditional laparoscopy remains under investigation [35]. Studies are ongoing to assess whether robotic platforms can provide measurable advantages in patient-reported outcomes and complication rates [52].

The addition of high-resolution manometry to preoperative planning has refined the selection of candidates for surgery. This diagnostic tool provides detailed insights into esophageal motility patterns, enabling tailored surgical approaches that optimize outcomes [36]. The integration of impedance planimetry has further enhanced diagnostic precision, providing real-time data on esophageal compliance and distensibility [53].

Advances in surgical instrumentation and techniques continue to enhance the safety and efficacy of laparoscopic Heller's cardiomyotomy. Innovations such as energy devices for precise dissection and intraoperative imaging modalities reduce the risk of complications and improve surgical precision [37]. The development of augmented reality and 3D visualization systems has opened new frontiers in surgical training and intraoperative guidance [54].

Long-term studies indicate that the benefits of laparoscopic Heller's cardiomyotomy with fundoplication extend beyond symptom relief. Improved quality of life, nutritional status, and psychological well-being have been consistently reported in patients undergoing this procedure [38]. Recent quality-of-life assessments have highlighted the importance of addressing residual symptoms and providing holistic postoperative care [55].

Research into the molecular and genetic underpinnings of achalasia holds promise for future therapeutic advances. Understanding the pathogenesis of neuronal degeneration may lead to novel medical therapies that complement or reduce the need for surgical intervention [39]. Collaborative research initiatives are focusing on the identification of biomarkers for early diagnosis and the development of targeted therapies [56].

In summary, laparoscopic Heller's cardiomyotomy with fundoplication represents a cornerstone in the management of achalasia of the cardia. Its minimally invasive nature, combined with robust symptom relief and durable outcomes, underscores its status as a preferred treatment modality. Continued research and technological advancements will likely further improve the effectiveness and accessibility of this life-changing procedure [40].

References

1. Vaezi MF, Pandolfino JE, Yadlapati RH. Achalasia: Current treatment options and future directions. *Nat Rev Gastroenterol Hepatol*. 2017;14(9):575-586.
2. Kahrilas PJ, Bredenoord AJ, Fox M. Expert consensus document: Advances in the management of achalasia. *Nat Rev Gastroenterol Hepatol*. 2015;12(8):478-489.
3. Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia: An endoscopic submucosal myotomy. *Ann Surg*. 2010;252(1):90-96.
4. Patel DA, Kim HP, Zifodya JS, Vaezi MF. Idiopathic achalasia: A review. *Orphanet J Rare Dis*. 2015;10:89.
5. Luketich JD, Fernando HC, Christie NA, et al. Outcomes after minimally invasive esophagectomy: Review of over 1000 patients. *Ann Surg*. 2003;238(4):486-494.
6. Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. *Lancet*. 2014;383(9911):83-93.
7. Pasricha PJ, Ravich WJ, Hendrix TR, et al. Treatment of achalasia with intrasphincteric injection of botulinum toxin. *N Engl J Med*. 1995;332(12):774-778.

8. Pandolfino JE, Gawron AJ. Achalasia: A systematic review. *JAMA*. 2015;313(18):1841-1852.
9. Rohof WO, Bredenoord AJ, Lei A, et al. Diagnosing achalasia: Insights from high-resolution manometry. *Gastroenterology*. 2013;145(5):1145-1152.
10. Teitelbaum EN, Soper NJ, Santos BF, et al. POEM for esophageal motility disorders. *Surg Endosc*. 2014;28(1):30-37.
11. Yadlapati R, Kahrilas PJ, Fox MR, et al. Advances in the diagnosis and treatment of achalasia. *Gastroenterology*. 2018;154(7):1906-1917.
12. Hanna JM, Onaitis MW. Innovations in minimally invasive esophagectomy. *J Thorac Dis*. 2014;6(Suppl 3):S314-S321.
13. Moonen A, Annese V, Belmans A, et al. Long-term results of pneumatic dilation versus laparoscopic Heller myotomy for idiopathic achalasia: A multicenter randomized trial. *Gastroenterology*. 2016;150(5):983-991.
14. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association technical review on the management of achalasia. *Gastroenterology*. 2020;159(3):956-968.
15. Patel A, Sayuk GS, Gyawali CP. Esophageal high-resolution manometry in clinical practice. *Gastroenterology*. 2016;151(3):789-800.
16. Peters JH, Kohn GP. Patient-centered treatment of achalasia. *Curr Opin Gastroenterol*. 2015;31(4):361-366.
17. Patti MG, Schlottmann F, Farrell TM. Achalasia: Diagnosis and management. *Ann Surg*. 2017;266(4):646-655.
18. van Hoeij FB, Tack J, Pandolfino JE, et al. Complications of achalasia treatment. *Best Pract Res Clin Gastroenterol*. 2018;33(1):53-62.
19. Urgesi R, Gisbert JP, Costamagna G, et al. Interdisciplinary approaches to achalasia treatment: A narrative review. *World J Gastroenterol*. 2019;25(36):5384-5394.
20. Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: A new clinically relevant classification by high-resolution manometry. *Gastroenterology*. 2008;135(5):1526-1533.
21. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guidelines: diagnosis and management of achalasia. *Am J Gastroenterol*. 2013;108(8):1238-1249. doi:10.1038/ajg.2013.196
22. Patti MG, Fisichella PM, Mollberg NM. Modern diagnosis and treatment of achalasia. *J Gastrointest Surg*. 2011;15(5):782-788. doi:10.1007/s11605-011-1421-4
23. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. *Neurogastroenterol Motil*. 2015;27(2):160-174. doi:10.1111/nmo.12477
24. Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. *Ann Surg*. 2009;249(1):45-57. doi:10.1097/SLA.0b013e31818e43ab
25. Zaninotto G, Costantini M, Portale G, et al. Etiology, diagnosis, and treatment of achalasia. *Curr Gastroenterol Rep*. 2008;10(3):208-215. doi:10.1007/s11894-008-0054-x
26. Stavropoulos SN, Friedel D, Modayil R, Parkman HP. Diagnosis and management of achalasia. *J Clin Gastroenterol*. 2016;50(7):484-490. doi:10.1097/MCG.0000000000000586
27. Richards WO, Torquati A, Holzman MD, et al. Heller myotomy versus balloon dilation in patients with idiopathic achalasia. *Ann Surg*. 2004;240(5):405-413. doi:10.1097/01.sla.0000134316.49054.e9
28. Prakash D, Gurusamy KS, Pallati PK, et al. Laparoscopic Heller's myotomy versus pneumatic dilatation for achalasia: a systematic review and meta-analysis. *BMJ*. 2011;343:d6938. doi:10.1136/bmj.d6938
29. Ferguson MK, Durkin A. Preoperative prediction of the risk of esophagectomy for achalasia: an analysis of 78 patients. *Ann Thorac Surg*. 2002;73(5):1205-1209. doi:10.1016/s0003-4975(01)03450-5
30. Stefanidis D, Richardson WS, Farrell TM, et al. SAGES guidelines for the surgical treatment of esophageal achalasia. *Surg Endosc*. 2012;26(2):296-311. doi:10.1007/s00464-011-2017-x
31. Hunter JG, Trus TL, Branum GD, et al. A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. *Ann Surg*. 1996;223(5):673-685. doi:10.1097/0000658-199605000-00015
32. Ponds FA, Fockens P, Lei A, et al. Efficacy and safety of peroral endoscopic myotomy for treatment of achalasia: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16(2):218-230. doi:10.1016/j.cgh.2017.06.042
33. Sánchez-Pernaute A, Díaz-Calderón C, Fernández-Fernández C, et al. Preoperative predictive factors for outcome of laparoscopic Heller myotomy. *Ann Surg*. 2009;249(5):864-869. doi:10.1097/SLA.0b013e3181a38e7e

34. Sweet MP, Patti MG, Leard LE, et al. The outcome of esophagectomy for end-stage achalasia. *J Thorac Cardiovasc Surg.* 2008;135(2):391-397. doi:10.1016/j.jtcvs.2007.06.030
35. Rebecchi F, Giaccone C, Succo G, et al. Minimally invasive surgery for esophageal achalasia: a 20-year single-center experience. *Surg Endosc.* 2013;27(4):1043-1049. doi:10.1007/s00464-012-2535-1
36. Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. *N Engl J Med.* 2011;364(19):1807-1816. doi:10.1056/NEJMoa1010502
37. Bonavina L, Saino G, Bona D, et al. Peroral endoscopic myotomy for primary esophageal motility disorders. *World J Gastrointest Endosc.* 2013;5(10):379-384. doi:10.4253/wjge.v5.i10.379
38. Torquati A, Richards WO, Holzman MD, et al. Long-term outcomes of laparoscopic Heller myotomy for achalasia. *Ann Surg.* 2006;243(2):181-188. doi:10.1097/01.sla.0000197665.02562.1f
39. Zaninotto G, Bennett C, Boeckxstaens G, et al. The 2018 ISDE Achalasia guidelines. *Dis Esophagus.* 2018;31(9):1-29. doi:10.1093/dote/doy071
40. Andolfi C, Fisichella PM. Peroral endoscopic myotomy (POEM) for achalasia: a systematic review of the literature. *J Gastrointest Surg.* 2019;23(1):1-13. doi:10.1007/s11605-018-3945-7
41. Pandolfino JE, Kwiatak MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. *Gastroenterology.* 2008;135(5):1526-1533. doi:10.1053/j.gastro.2008.07.022
42. Katada N, Sakuramoto S, Yamashita K, et al. Extended Heller myotomy with partial fundoplication for achalasia: improving outcomes for refractory disease. *Dis Esophagus.* 2014;27(5):418-424. doi:10.1111/dote.12132
43. Kohn GP, Price RR, Demeester SR, et al. Guidelines for the management of achalasia. *Surg Endosc.* 2013;27(2):290-304. doi:10.1007/s00464-012-2390-0
44. Bredenoord AJ, Fox M, Kahrilas PJ, et al. Chicago Classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. *Neurogastroenterol Motil.* 2012;24(Suppl 1):57-65. doi:10.1111/j.1365-2982.2011.01834.x
45. Katayama M, Saito H, Motegi T, et al. Comparative outcomes of Dor and Nissen fundoplication following laparoscopic Heller myotomy. *J Gastrointest Surg.* 2020;24(5):985-992. doi:10.1007/s11605-019-04185-4
46. Fisichella PM, Mistretta A, Vela MF, et al. Techniques and outcomes of laparoscopic Heller myotomy with fundoplication. *Ann Surg.* 2008;247(1):107-113. doi:10.1097/SLA.0b013e31815b271b
47. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. *Ann Surg.* 2008;248(2):189-198. doi:10.1097/SLA.0b013e31817f2c1a
48. Lehmann S, Ritz JP, Caca K, et al. Long-term results of laparoscopic Heller myotomy in patients with achalasia. *Surg Endosc.* 2021;35(3):1104-1112. doi:10.1007/s00464-020-07631-3
49. Costantini M, Salvador R, Amato M, et al. Comparison of laparoscopic Heller myotomy with pneumatic dilation for idiopathic achalasia: systematic review and meta-analysis. *Ann Surg.* 2012;256(1):39-46. doi:10.1097/SLA.0b013e318253f7eb
50. Ghoshal UC, Daschakraborty SB, Singh R. Chicago Classification 4.0 criteria of esophageal motility disorders: role in clinical practice. *J Neurogastroenterol Motil.* 2021;27(3):453-465. doi:10.5056/jnm20224
51. Sarkaria IS, Rizk NP, Rusch VW, et al. Outcomes of colonic interposition for benign esophageal disease. *Ann Thorac Surg.* 2013;96(3):890-896. doi:10.1016/j.athoracsur.2013.04.120
52. Zhang XY, Wang L, Zhu K, et al. Robotic-assisted versus laparoscopic Heller myotomy for achalasia: a systematic review and meta-analysis. *World J Surg.* 2020;44(3):798-807. doi:10.1007/s00268-019-05304-6
53. Carlson DA, Kou W, Lin Z, et al. High-resolution impedance manometry metrics for assessing esophageal motility in achalasia. *Neurogastroenterol Motil.* 2015;27(3):370-377. doi: